Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer

References

• Abdelnour-Berchtold, E., Cerantola, Y., Roulin, D., Dormond-Meuwly, A., Demartines, N., Dormond, O. (2010). Rapamycin-mediated FOXO1 inactivation reduces the anticancer efficacy of rapamycin. Anticancer Res 30:799–804.
   PubMed Web of Science ®Google Scholar
• Abe, T, Unno, M., Onogawa, T., Tokui, T., Kondo, T. N., Nakagomi, R., et al. (2001). LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120:1689–1699.
   PubMed Web of Science ®Google Scholar
• Abuli, A., Bessa, X., Gonzalez, J. R., Ruiz-Ponte, C., Caceres, A., Munoz, J., et al. (2010). Susceptibility genetic variants associated with colorectal cancer risk correlate with cancer phenotype. Gastroenterology 139:788–796.
   PubMed Web of Science ®Google Scholar
• Alberts, D. S., Martinez, M. E., Hess, L. M., Einspahr, J. G., Green, S. B., Bhattacharyya, A. K., et al. (2005). Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 97:846–853.
   PubMed Web of Science ®Google Scholar
• Alberts, D. S., Martinez, M. E., Roe, D. J., Guillen-Rodriguez, J. M., Marshall, J. R., van Leeuwen, J. B., et al. (2000). Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians’ Network. N Engl J Med 342:1156–1162.
   PubMed Web of Science ®Google Scholar
• Allegra, C. J., Yothers, G., O’Connell, M. J., Sharif, S., Colangelo, L. H., Lopa, S. H., et al. (2009). Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 27:3385–3390.
   PubMed Web of Science ®Google Scholar
• Andre, T, Boni, C, Mounedji-Boudiaf, L, Navarro, M, Tabernero, J, Hickish, T, et al. (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351.
   PubMed Web of Science ®Google Scholar
• Andre, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., et al. (2009). Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116.
   PubMed Web of Science ®Google Scholar
• Andre, T, Colin, P, Louvet, C, Gamelin, E, Bouche, O, Achille, E, et al. (2003). Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 21:2896–2903.
   PubMed Web of Science ®Google Scholar
• Andre, T., Louvet, C., Maindrault-Goebel, F., Couteau, C., Mabro, M., Lotz, J. P., et al. (1999). CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer, 35, 1343–7.
   PubMed Web of Science ®Google Scholar
• Andre, T., Quinaux, E., Louvet, C., Colin, P., Gamelin, E., Bouche, O., et al. (2007). Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 25:3732–3738.
   PubMed Web of Science ®Google Scholar
• Arango, D., Mariadason, J. M., Wilson, A. J., Yang, W., Corner, G. A., Nicholas, C., et al. (2003). c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. Br J Cancer 89:1757–1765.
   PubMed Web of Science ®Google Scholar
• Arango, D., Wilson, A. J., Shi, Q., Corner, G. A., Aranes, M. J., Nicholas, C., et al. (2004). Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91:1931–1946.
   PubMed Web of Science ®Google Scholar
• Arnould, S., Hennebelle, I., Canal, P., Bugat, R., Guichard, S. (2003). Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 39:112–119.
   PubMed Web of Science ®Google Scholar
• Ashley, A. C., Sargent, D. J., Alberts, S. R., Grothey, A., Campbell, M. E., Morton, R. F., et al. (2007). Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX): intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Cancer 110:670–677.
   PubMed Web of Science ®Google Scholar
• Ballestero, M. R., Monte, M. J., Briz, O., Jimenez, F., Gonzalez-San Martin, F., Marin, J. J. (2006). Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochem Pharmacol 72:729–738.
   PubMed Web of Science ®Google Scholar
• Baron, J. A., Beach, M., Mandel, J. S., van Stolk, R. U., Haile, R. W., Sandler, R. S., et al. (1999). Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 340:101–107.
   PubMed Web of Science ®Google Scholar
• Becerra, C. R., Frenkel, E. P., Ashfaq, R., Gaynor, R. B. (2003). Increased toxicity and lack of efficacy of rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: a phase II study. Int J Cancer 105:868–872.
   PubMed Web of Science ®Google Scholar
• Bennett, A., Del Tacca, M. (1975). Proceedings: prostaglandins in human colonic carcinoma. Gut 16:409.
   PubMed Web of Science ®Google Scholar
• Benson, A. B., 3rd, Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., et al. (2004). American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408–3419.
   PubMed Web of Science ®Google Scholar
• Beresford, S. A., Johnson, K. C., Ritenbaugh, C., Lasser, N. L., Snetselaar, L. G., Black, H. R., et al. (2006). Low-fat dietary pattern and risk of colorectal cancer: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 295:643–654.
   PubMed Web of Science ®Google Scholar
• Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M., Breazna, A., Kim, K., et al. (2009). Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) 2:310–321.
   PubMed Web of Science ®Google Scholar
• Bingham, S. A., Day, N. E., Luben, R., Ferrari, P., Slimani, N., Norat, T., et al. (2003). Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 361:1496–1501.
   PubMed Web of Science ®Google Scholar
• Bonithon-Kopp, C., Kronborg, O., Giacosa, A., Rath, U., Faivre, J. (2000). Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet 356:1300–1306.
   PubMed Web of Science ®Google Scholar
• Boonsong, A., Marsh, S., Rooney, P. H., Stevenson, D. A., Cassidy, J., McLeod, H. L. (2000). Characterization of the topoisomerase I locus in human colorectal cancer. Cancer Genet Cytogenet 121:56–60.
   PubMed Web of Science ®Google Scholar
• Briz, O., Macias, R. I., Vallejo, M., Silva, A., Serrano, M. A., Marin, J. J. (2003). Usefulness of liposomes loaded with cytostatic bile acid derivatives to circumvent chemotherapy resistance of enterohepatic tumors. Mol Pharmacol 63:742–750.
   PubMed Web of Science ®Google Scholar
• Budd, G. T., Fleming, T. R., Bukowski, R. M., McCracken, J. D., Rivkin, S. E., O’Bryan, R. M., et al. (1987). 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group Study. J Clin Oncol 5:272–277.
   PubMed Web of Science ®Google Scholar
• Bujanda, L., Sarasqueta, C., Hijona, E., Hijona, L., Cosme, A., Gil, I., et al. (2010). Colorectal cancer prognosis twenty years later. World J Gastroenterol 16:862–867.
   PubMed Web of Science ®Google Scholar
• Buyse, M., Zeleniuch-Jacquotte, A., Chalmers, T. C. (1988). Adjuvant therapy of colorectal cancer. Why we still don’t know. JAMA 259:3571–3578.
   PubMed Web of Science ®Google Scholar
• Caponigro, F., Lacombe, D., Twelves, C., Bauer, J., Govaerts, A. S., Marreaud, S., et al. (2009). An EORTC phase I study of bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. Eur J Cancer 45:48–55.
   PubMed Web of Science ®Google Scholar
• Carrato, A., Köhne, C., Bedenne, L., Popov, I., Bouche, O., Gaspar, E., et al. (2006). Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer: preliminary analysis of the PETACC-2-study. 2006 ASCO Annual Meeting Proceedings J Clin Oncol 24:18S.
   Google Scholar
• Cascinu, S., Berardi, R., Salvagni, S., Beretta, G. D., Catalano, V., Pucci, F., et al. (2008). A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification, and NF-kB activation. Br J Cancer 98:71–76.
   PubMed Web of Science ®Google Scholar
• Cassidy, J, Clarke, S, Diaz-Rubio, E, Scheithauer, W, Figer, A, Wong, R, et al. (2008). Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006–2012.
   PubMed Web of Science ®Google Scholar
• Cassidy, J., Douillard, J. Y., Twelves, C., McKendrick, J. J., Scheithauer, W., Bustova, I., et al. (2006). Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes’ C colon cancer: the X-ACT trial. Br J Cancer 94:1122–1129.
   PubMed Web of Science ®Google Scholar
• Cassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., et al. (2004). XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22:2084–2091.
   PubMed Web of Science ®Google Scholar
• Castells, A., Marzo-Castillejo, M., Mascort, J. J., Amador, F. J., Andreu, M., Bellas, B., et al. (2009). [Clinical practice guideline. Prevention of colorectal cancer. 2009 update. Asociacion Espanola de Gastroenterologia]. [Article in Spanish]. Gastroenterol Hepatol 32:717 e1–58.
   Web of Science ®Google Scholar
• Chan, A. T., Giovannucci, E. L. (2010). Primary prevention of colorectal cancer. Gastroenterology 138:2029–2043.
   PubMed Web of Science ®Google Scholar
• Chao, C. C., Huang, Y. T., Ma, C. M., Chou, W. Y., Lin-Chao, S. (1992). Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug-resistant human colon cancer cell line. Mol Pharmacol 41:69–75.
   PubMed Web of Science ®Google Scholar
• Chen, J., Huang, X. F., Katsifis, A. (2010). Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer. J Cell Biochem 111:1082–1086.
   Web of Science ®Google Scholar
• Chen, R., Nelson, J. A. (2000). Role of organic cation transporters in the renal secretion of nucleosides. Biochem Pharmacol 60:215–219.
   PubMed Web of Science ®Google Scholar
• Chibaudel, B., Maindrault-Goebel, F., Lledo, G., Mineur, L., Andre, T., Bennamoun, M., et al. (2009a). Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 27:5727–5733.
   PubMed Web of Science ®Google Scholar
• Chibaudel, B., Tournigand, C., Artru, P., Andre, T., Cervantes, A., Figer, A., et al. (2009b). FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 Study. Ann Oncol 20:1383–1386.
   PubMed Web of Science ®Google Scholar
• Chlebowski, R. T., Wactawski-Wende, J., Ritenbaugh, C., Hubbell, F. A., Ascensao, J., Rodabough, R. J., et al. (2004). Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350:991–1004.
   PubMed Web of Science ®Google Scholar
• Cho, E., Smith-Warner, S. A., Spiegelman, D., Beeson, W. L., van den Brandt, P. A., Colditz, G. A., et al. (2004). Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst 96:1015–1022.
   PubMed Web of Science ®Google Scholar
• Chu, E., Koeller, D. M., Johnston, P. G., Zinn, S., Allegra, C. J. (1993). Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. Mol Pharmacol 43:527–533.
   PubMed Web of Science ®Google Scholar
• Ciardiello, F., Tortora, G. (2001). A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7:2958–2970.
   PubMed Web of Science ®Google Scholar
• Cohen, A. M. (1991). Surgical considerations in patients with cancer of the colon and rectum. Semin Oncol 18:381–387.
   PubMed Web of Science ®Google Scholar
• Cole, B. F., Baron, J. A., Sandler, R. S., Haile, R. W., Ahnen, D. J., Bresalier, R. S., et al. (2007). Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 297:2351–2359.
   PubMed Web of Science ®Google Scholar
• Comella, P., Palmieri, G., Lorusso, V., Catalano, G., Nicollela, D., Ianniello, G. P., et al. (1996). Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies. Eur J Cancer 32A:1719–1726.
   PubMed Web of Science ®Google Scholar
• Compton, C. C., Fielding, L. P., Burgart, L. J., Conley, B., Cooper, H. S., Hamilton, S. R., et al. (2000). Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:979–994.
   PubMed Web of Science ®Google Scholar
• Compton, C. C., Greene, F. L. (2004). The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 54:295–308.
   PubMed Web of Science ®Google Scholar
• Cook, N. R., Lee, I. M., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., et al. (2005). Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294:47–55.
   PubMed Web of Science ®Google Scholar
• Cummings, J., Ethell, B. T., Jardine, L., Boyd, G., Macpherson, J. S., Burchell, B., et al. (2003). Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Res 63:8443–8450.
   PubMed Web of Science ®Google Scholar
• Cunningham, D. (1998). Mature results from three large controlled studies with raltitrexed (‘Tomudex’). Br J Cancer 77:15–21.
   PubMed Web of Science ®Google Scholar
• Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., et al. (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345.
   PubMed Web of Science ®Google Scholar
• Cuzick, J., Otto, F., Baron, J. A., Brown, P. H., Burn, J., Greenwald, P., et al. (2009). Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10:501–507.
   PubMed Web of Science ®Google Scholar
• Dart, D. A., Picksley, S. M., Cooper, P. A., Double, J. A., Bibby, M. C. (2004). The role of p53 in the chemotherapeutic responses to cisplatin, doxorubicin and 5-fluorouracil treatment. Int J Oncol 24:115–125.
   PubMed Web of Science ®Google Scholar
• de Gramont, A., Bosset, J. F., Milan, C., Rougier, P., Bouche, O., Etienne, P. L., et al. (1997). Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15:808–815.
   PubMed Web of Science ®Google Scholar
• de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., et al. (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947.
   PubMed Web of Science ®Google Scholar
• Dencausse, Y., Hartung, G., Sturm, J., Kopp-Schneider, A., Hagmuller, E., Wojatschek, C., et al. (2002). Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin. Onkologie 25:426–430.
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., et al. (2008). Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705–5712.
   PubMed Web of Science ®Google Scholar
• Donada, M., Bonin, S., Nardon, E., De Pellegrin, A., Decorti, G., Stanta, G. (2011). Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability. J Cancer Res Clin Oncol 137:201–210.
   PubMed Web of Science ®Google Scholar
• Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., et al. (1998). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615–1622.
   PubMed Web of Science ®Google Scholar
• DuBois, R. N., Radhika, A., Reddy, B. S., Entingh, A. J. (1996). Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 110:1259–1262.
   PubMed Web of Science ®Google Scholar
• Dudkin, L., Dilling, M. B., Cheshire, P. J., Harwood, F. C., Hollingshead, M., Arbuck, S. G., et al. (2001). Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 7:1758–1764.
   PubMed Web of Science ®Google Scholar
• Dunn, E. F., Iida, M., Myers, R. A., Campbell, D. A., Hintz, K. A., Armstrong, E. A., et al. (2011). Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene 30:561–574.
   Google Scholar
• Efferth, T., Konkimalla, V. B., Wang, Y. F., Sauerbrey, A., Meinhardt, S., Zintl, F., et al. (2008). Prediction of broad spectrum resistance of tumors towards anticancer drugs. Clin Cancer Res 14:2405–2412.
   PubMed Web of Science ®Google Scholar
• El-Rayes, B. F., Zalupski, M. M., Manza, S. G., Rusin, B., Ferris, A. M., Vaishampayan, U., et al. (2008). Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. Cancer Chemother Pharmacol 61:283–289.
   PubMed Web of Science ®Google Scholar
• Elias, D., Benizri, E., Di Pietrantonio, D., Menegon, P., Malka, D., Raynard, B. (2007). Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol 14:509–514.
   PubMed Web of Science ®Google Scholar
• Elit, L. (2002). CCI-779 Wyeth. Curr Opin Investig Drugs 3:1249–1253.
   PubMedGoogle Scholar
• Endo, K., Kohnoe, S., Watanabe, A., Tashiro, H., Sakata, H., Morita, M., et al. (2009). Clinical significance of Smac/DIABLO expression in colorectal cancer. Oncol Rep 21:351–355.
   PubMed Web of Science ®Google Scholar
• Endo, Y., Obata, T., Murata, D., Ito, M., Sakamoto, K., Fukushima, M., et al. (2007). Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides. Cancer Sci 98:1633–1637.
   PubMed Web of Science ®Google Scholar
• Etienne, M. C., Chazal, M., Laurent-Puig, P., Magne, N., Rosty, C., Formento, J. L., et al. (2002). Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 20:2832–2843.
   PubMed Web of Science ®Google Scholar
• Fakih, M. G., Pendyala, L., Fetterly, G., Toth, K., Zwiebel, J. A., Espinoza-Delgado, I., et al. (2009). A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res 15:3189–3195.
   PubMed Web of Science ®Google Scholar
• Falcone, A, Ricci, S, Brunetti, I, Pfanner, E, Allegrini, G, Barbara, C, et al. (2007). Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670–1676.
   PubMed Web of Science ®Google Scholar
• Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917.
   PubMed Web of Science ®Google Scholar
• Fink, D., Aebi, S., Howell, S. B. (1998). The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4:1–6.
   PubMed Web of Science ®Google Scholar
• Folprecht, G., Lutz, M. P., Schoffski, P., Seufferlein, T., Nolting, A., Pollert, P., et al. (2006). Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17:450–456.
   PubMed Web of Science ®Google Scholar
• Folprecht, G., Tabernero, J., Kohne, C. H., Zacharchuk, C., Paz-Ares, L., Rojo, F., et al. (2008). Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer. Clin Cancer Res 14:215–223.
   PubMed Web of Science ®Google Scholar
• Fong, T. A., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T. J., et al. (1999). SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99–106.
   PubMed Web of Science ®Google Scholar
• Fuchs, C. S., Marshall, J., Mitchell, E., Wierzbicki, R., Ganju, V., Jeffery, M., et al. (2007). Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25:4779–4786.
   PubMed Web of Science ®Google Scholar
• Fulda, S. (2009). Inhibitor of apoptosis (IAP) proteins: novel insights into the cancer-relevant targets for cell death induction. ACS Chem Biol 4:499–501.
   PubMed Web of Science ®Google Scholar
• Gallagher, DJ, Kemeny, N. (2010). Metastatic colorectal cancer: from improved survival to potential cure. Oncology 78:237–248.
   PubMed Web of Science ®Google Scholar
• Gann, P. H., Manson, J. E., Glynn, R. J., Buring, J. E., Hennekens, C. H. (1993). Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85:1220–1224.
   PubMed Web of Science ®Google Scholar
• Garland, C. F., Garland, F. C., Gorham, E. D. (1999). Calcium and vitamin D. Their potential roles in colon and breast cancer prevention. Ann N Y Acad Sci 889:107–119.
   PubMed Web of Science ®Google Scholar
• Giardiello, F. M., Hamilton, S. R., Hylind, L. M., Yang, V. W., Tamez, P., Casero, R. A., Jr. (1997). Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Cancer Res 57:199–201.
   PubMed Web of Science ®Google Scholar
• Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., et al. (1993). Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316.
   PubMed Web of Science ®Google Scholar
• Gill, S., Loprinzi, C. L., Sargent, D. J., Thome, S. D., Alberts, S. R., Haller, D. G., et al. (2004). Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22:1797–1806.
   PubMed Web of Science ®Google Scholar
• Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., et al. (2004). A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30.
   PubMed Web of Science ®Google Scholar
• Gourdier, I., Del Rio, M., Crabbe, L., Candeil, L., Copois, V., Ychou, M., et al. (2002). Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. FEBS Lett 529:232–236.
   Google Scholar
• Gradilone, A., Pulcinelli, F. M., Lotti, L. V., Trifiro, E., Martino, S., Gandini, O., et al. (2008). Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Curr Cancer Drug Targets 8:414–420.
   PubMed Web of Science ®Google Scholar
• Haller, D. G., Catalano, P. J., Macdonald, J. S., O’Rourke, M. A., Frontiera, M. S., Jackson, D. V., et al. (2005). Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23:8671–8678.
   PubMed Web of Science ®Google Scholar
• Haller, D. G., Tabernero, J., Maroun, J., de Braud, F., Price, T., Van Cutsem, E., et al. (2011). Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29:1465–1471.
   PubMed Web of Science ®Google Scholar
• Hayward, R. L., Macpherson, J. S., Cummings, J., Monia, B. P., Smyth, J. F., Jodrell, D. I. (2004). Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: genetic evidence for specificity of the antisense effect. Mol Cancer Ther 3:169–178.
   PubMed Web of Science ®Google Scholar
• Hecht, J. R., Patnaik, A., Berlin, J., Venook, A., Malik, I., Tchekmedyian, S., et al. (2007). Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 110:980–988.
   PubMed Web of Science ®Google Scholar
• Hinoshita, E., Uchiumi, T., Taguchi, K., Kinukawa, N., Tsuneyoshi, M., Maehara, Y., et al. (2000). Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res 6:2401–2407.
   PubMed Web of Science ®Google Scholar
• Hishikawa, Y., Kohno, H., Ueda, S., Kimoto, T., Dhar, D. K., Kubota, H., et al. (2001). Expression of metallothionein in colorectal cancers and synchronous liver metastases. Oncology 61:162–167.
   PubMed Web of Science ®Google Scholar
• Hixson, L. J., Garewal, H. S., McGee, D. L., Sloan, D., Fennerty, M. B., Sampliner, R. E., et al. (1993). Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa. Cancer Epidemiol Biomarkers Prev 2:369–374.
   PubMed Web of Science ®Google Scholar
• Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., et al. (2001). Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282–2292.
   PubMed Web of Science ®Google Scholar
• Holzer, A. K., Manorek, G. H., Howell, S. B. (2006a). Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol 70:1390–1394.
   PubMed Web of Science ®Google Scholar
• Holzer, A. K., Varki, N. M., Le, Q. T., Gibson, M. A., Naredi, P., Howell, S. B. (2006b). Expression of the human copper influx transporter 1 in normal and malignant human tissues. J Histochem Cytochem 54:1041–1049.
   PubMed Web of Science ®Google Scholar
• Honjo, Y., Hrycyna, C. A., Yan, Q. W., Medina-Perez, W. Y., Robey, R. W., van de Laar, A., et al. (2001). Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61:6635–6639.
   PubMed Web of Science ®Google Scholar
• Huang, Y., Sadee, W. (2006). Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett 239:168–182.
   PubMed Web of Science ®Google Scholar
• Huerta, S., Heinzerling, J. H., Anguiano-Hernandez, Y. M., Huerta-Yepez, S., Lin, J., Chen, D., et al. (2007). Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. J Surg Res 142:184–194.
   PubMed Web of Science ®Google Scholar
• Hurwitz, H, Fehrenbacher, L, Novotny, W, Cartwright, T, Hainsworth, J, Heim, W, et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342.
   PubMed Web of Science ®Google Scholar
• Itzkowitz, S. H., Harpaz, N. (2004). Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126:1634–1648.
   PubMed Web of Science ®Google Scholar
• Izquierdo, M. A., Scheffer, G. L., Flens, M. J., Giaccone, G., Broxterman, H. J., Meijer, C. J., et al. (1996). Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 148:877–887.
   PubMed Web of Science ®Google Scholar
• Jackson, N. A., Barrueco, J., Soufi-Mahjoubi, R., Marshall, J., Mitchell, E., Zhang, X., et al. (2009). Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer 115:2617–2629.
   PubMed Web of Science ®Google Scholar
• Jacobs, E. T., Jiang, R., Alberts, D. S., Greenberg, E. R., Gunter, E. W., Karagas, M. R., et al. (2004). Selenium and colorectal adenoma: results of a pooled analysis. J Natl Cancer Inst 96:1669–1675.
   PubMed Web of Science ®Google Scholar
• Jaffe, B. M. (1974). Prostaglandins and cancer: an update. Prostaglandins 6:453–461.
   PubMed Web of Science ®Google Scholar
• Jenab, M., Bueno-de-Mesquita, H. B., Ferrari, P., van Duijnhoven, F. J., Norat, T., Pischon, T., et al. (2010). Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations:a nested case-control study. BMJ 340:b5500.
   PubMed Web of Science ®Google Scholar
• Jimeno, A., Gravalos, C., Escudero, P., Sevilla, I., Vega-Villegas, M. E., Alonso, V., et al. (2008). Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer. Clin Transl Oncol 10:52–57.
   PubMed Web of Science ®Google Scholar
• Johnston, P. G., Lenz, H. J., Leichman, C. G., Danenberg, K. D., Allegra, C. J., Danenberg, P. V., et al. (1995). Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407–1412.
   PubMed Web of Science ®Google Scholar
• Jover, R., Zapater, P., Castells, A., Llor, X., Andreu, M., Cubiella, J., et al. (2009). The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 45:365–373.
   PubMed Web of Science ®Google Scholar
• Kachnic, L. A. (2006). Should preoperative or postoperative therapy be administered in the management of rectal cancer? Semin Oncol 33:S64–S69.
   PubMed Web of Science ®Google Scholar
• Kaiser, S., Park, Y. K., Franklin, J. L., Halberg, R. B., Yu, M., Jessen, W. J., et al. (2007). Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 8: R131.
   PubMed Web of Science ®Google Scholar
• Kim, Y. I. (2003). Role of folate in colon cancer development and progression. J Nutr 133:3731S–3739S.
   PubMed Web of Science ®Google Scholar
• Kitazono, M., Sumizawa, T., Takebayashi, Y., Chen, Z. S., Furukawa, T., Nagayama, S., et al. (1999). Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 91:1647–1653.
   PubMed Web of Science ®Google Scholar
• Kortmansky, J., Shah, M. A., Kaubisch, A., Weyerbacher, A., Yi, S., Tong, W., et al. (2005). Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol 23:1875–1884.
   PubMed Web of Science ®Google Scholar
• Kozuch, P., Malamud, S., Wasserman, C., Homel, P., Mirzoyev, T., Grossbard, M. (2009). Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer. Clin Colorectal Cancer 8:38–42.
   PubMed Web of Science ®Google Scholar
• Kuebler, J. P., Wieand, H. S., O’Connell, M. J., Smith, R. E., Colangelo, L. H., Yothers, G., et al. (2007). Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25:2198–2204.
   PubMed Web of Science ®Google Scholar
• Kuo, M. T., Bao, J. J., Curley, S. A., Ikeguchi, M., Johnston, D. A., Ishikawa, T. (1996). Frequent coordinated overexpression of the MRP/GS-X pump and gamma-glutamylcysteine synthetase genes in human colorectal cancers. Cancer Res 56:3642–3644.
   PubMed Web of Science ®Google Scholar
• Kusuhara, H., Sugiyama, Y. (2007). ATP-binding cassette, subfamily G (ABCG family). Pflugers Arch 453:735–744.
   PubMed Web of Science ®Google Scholar
• Lacy, A. M., Garcia-Valdecasas, J. C., Delgado, S., Castells, A., Taura, P., Pique, J. M., et al. (2002). Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet 359:2224–2229.
   PubMed Web of Science ®Google Scholar
• Laheru, D., Croghan, G., Bukowski, R., Rudek, M., Messersmith, W., Erlichman, C., et al. (2008). A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. Clin Cancer Res 14:5602–5609.
   PubMed Web of Science ®Google Scholar
• Lashner, B. A., Provencher, K. S., Seidner, D. L., Knesebeck, A., Brzezinski, A. (1997). The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 112:29–32.
   PubMed Web of Science ®Google Scholar
• Lazaris, A. C., Kavantzas, N. G., Zorzos, H. S., Tsavaris, N. V., Davaris, P. S. (2002). Markers of drug resistance in relapsing colon cancer. J Cancer Res Clin Oncol 128:114–118.
   PubMed Web of Science ®Google Scholar
• Lee, J. H., Soung, Y. H., Lee, J. W., Park, W. S., Kim, S. Y., Cho, Y. G., et al. (2004). Inactivating mutation of the pro-apoptotic gene BID in gastric cancer. J Pathol 202:439–445.
   PubMed Web of Science ®Google Scholar
• Lembersky, BC, Wieand, HS, Petrelli, NJ, O’Connell, MJ, Colangelo, LH, Smith, RE, et al. (2006). Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24:2059–2064.
   PubMed Web of Science ®Google Scholar
• Li, X. G., Haluska, P., Jr., Hsiang, Y. H., Bharti, A., Kufe, D. W., Rubin, E. H. (1996). Identification of topoisomerase I mutations affecting both DNA cleavage and interaction with camptothecin. Ann N Y Acad Sci 803:111–127.
   PubMed Web of Science ®Google Scholar
• Lin, X., Kim, H. K., Howell, S. B. (1999). The role of DNA mismatch repair in cisplatin mutagenicity. J Inorg Biochem 77:89–93.
   PubMed Web of Science ®Google Scholar
• Lockhart, AC, Cropp, GF, Berlin, JD, Donnelly, E, Schumaker, RD, Schaaf, LJ, et al. (2006). Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. Am J Clin Oncol 29:109–115.
   PubMed Web of Science ®Google Scholar
• Logan, R. F., Grainge, M. J., Shepherd, V. C., Armitage, N. C., Muir, K. R. (2008). Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 134:29–38.
   PubMed Web of Science ®Google Scholar
• Longley, D. B., Wilson, T. R., McEwan, M., Allen, W. L., McDermott, U., Galligan, L., et al. (2006). c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 25:838–848.
   Google Scholar
• Love, R. R., Jacoby, R., Newton, M. A., Tutsch, K. D., Simon, K., Pomplun, M., et al. (1998). A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev 7:989–992.
   PubMed Web of Science ®Google Scholar
• Ma, H., Li, X., Yang, Z., Okuno, S., Kawaguchi, T., Yagi, S., et al. (2011). High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate. J Surg Res June 25 171:684–90.
   PubMed Web of Science ®Google Scholar
• Magrini, R., Bhonde, M. R., Hanski, M. L., Notter, M., Scherubl, H., Boland, C. R., et al. (2002). Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer 101:23–31.
   PubMed Web of Science ®Google Scholar
• Maier, T. J., Schilling, K., Schmidt, R., Geisslinger, G., Grosch, S. (2004). Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 67:1469–1478.
   PubMed Web of Science ®Google Scholar
• Marcus, P. M., Newcomb, P. A. (1998). The association of calcium and vitamin D, and colon and rectal cancer in Wisconsin women. Int J Epidemiol 27:788–793.
   PubMed Web of Science ®Google Scholar
• Marin, J. J., Romero, M. R., Martinez-Becerra, P., Herraez, E., Briz, O. (2009). Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours. Curr Mol Med 9:1108–1129.
   PubMed Web of Science ®Google Scholar
• Marsh, S., McKay, J. A., Cassidy, J., McLeod, H. L. (2001). Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 19:383–386.
   PubMed Web of Science ®Google Scholar
• Martinez, C., Garcia-Martin, E., Pizarro, R. M., Garcia-Gamito, F. J., Agundez, J. A. (2002). Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy. Br J Cancer 87:681–686.
   PubMed Web of Science ®Google Scholar
• Martinez, M. E., Giovannucci, E., Jiang, R., Henning, S. M., Jacobs, E. T., Thompson, P., et al. (2006). Folate fortification, plasma folate, homocysteine and colorectal adenoma recurrence. Int J Cancer 119:1440–1446.
   PubMed Web of Science ®Google Scholar
• Martinez, M. E., Henning, S. M., Alberts, D. S. (2004). Folate and colorectal neoplasia: relation between plasma and dietary markers of folate and adenoma recurrence. Am J Clin Nutr 79:691–697.
   PubMed Web of Science ®Google Scholar
• Martinez, M. E., Marshall, J. R., Giovannucci, E. (2008). Diet and cancer prevention: the roles of observation and experimentation. Nat Rev Cancer 8:694–703.
   PubMed Web of Science ®Google Scholar
• Martinez-Balibrea, E., Martinez-Cardus, A., Musulen, E., Gines, A., Manzano, J. L., Aranda, E., et al. (2009). Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy. Int J Cancer 124:2905–2910.
   PubMed Web of Science ®Google Scholar
• Mason, J. B., Dickstein, A., Jacques, P. F., Haggarty, P., Selhub, J., Dallal, G., et al. (2007). A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomarkers Prev 16:1325–1329.
   PubMed Web of Science ®Google Scholar
• McCullough, M. L., Robertson, A. S., Rodriguez, C., Jacobs, E. J., Chao, A., Carolyn, J., et al. (2003). Calcium, vitamin D, dairy products, and risk of colorectal cancer in the Cancer Prevention Study II Nutrition Cohort (United States). Cancer Causes Control 14:1–12.
   PubMed Web of Science ®Google Scholar
• Meier, Y., Eloranta, J. J., Darimont, J., Ismair, M. G., Hiller, C., Fried, M., et al. (2007). Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos 35:590–594.
   PubMed Web of Science ®Google Scholar
• Meijer, C., Timmer, A., De Vries, E. G., Groten, J. P., Knol, A., Zwart, N., et al. (2000). Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer 85:777–781.
   PubMed Web of Science ®Google Scholar
• Merl, M., Hoimes, C., Pham, T., Saif, M. W. (2009). Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512). Expert Opin Investig Drugs 18:1257–1264.
   PubMed Web of Science ®Google Scholar
• Meyerhardt, J. A., Stuart, K., Fuchs, C. S., Zhu, A. X., Earle, C. C., Bhargava, P., et al. (2007). Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol 18:1185–1189.
   PubMed Web of Science ®Google Scholar
• Meyers, M., Wagner, M. W., Hwang, H. S., Kinsella, T. J., Boothman, D. A. (2001). Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 61:5193–5201.
   PubMed Web of Science ®Google Scholar
• Meyskens, F. L., Jr., McLaren, C. E., Pelot, D., Fujikawa-Brooks, S., Carpenter, P. M., Hawk, E., et al. (2008). Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 1:32–38.
   PubMed Web of Science ®Google Scholar
• Mita, M. M., Ochoa, L., Rowinsky, E. K., Kuhn, J., Schwartz, G., Hammond, L. A., et al. (2006). A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. Ann Oncol 17:313–321.
   PubMed Web of Science ®Google Scholar
• Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., et al. (1990). Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352–358.
   PubMed Web of Science ®Google Scholar
• Mol, C. D., Dougan, D. R., Schneider, T. R., Skene, R. J., Kraus, M. L., Scheibe, D. N., et al. (2004). Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279:31655–31663.
   PubMed Web of Science ®Google Scholar
• Montagut, C., Iglesias, M., Arumi, M., Bellosillo, B., Gallen, M., Martinez-Fernandez, A., et al. (2010). Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients. Br J Cancer 102:1137–1144.
   PubMed Web of Science ®Google Scholar
• Nannizzi, S., Veal, G. J., Giovannetti, E., Mey, V., Ricciardi, S., Ottley, C. J., et al. (2010). Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. Cancer Chemother Pharmacol 66:547–558.
   PubMed Web of Science ®Google Scholar
• Negri, F. V., Bozzetti, C., Lagrasta, C. A., Crafa, P., Bonasoni, M. P., Camisa, R., et al. (2010). PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer 102:162–164.
   PubMed Web of Science ®Google Scholar
• Nehls, O., Okech, T., Hsieh, C. J., Enzinger, T., Sarbia, M., Borchard, F., et al. (2007). Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Br J Cancer 96:1409–1418.
   PubMed Web of Science ®Google Scholar
• Nielsen, O. H., Munck, L. K. (2007). Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol 4:160–170.
   PubMedGoogle Scholar
• Nunes, M., Shi, C., Greenberger, L. M. (2004). Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes. Mol Cancer Ther 3:21–27.
   PubMed Web of Science ®Google Scholar
• O’Connell, M. J., Laurie, J. A., Kahn, M., Fitzgibbons, R. J., Jr., Erlichman, C., Shepherd, L., et al. (1998). Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16:295–300.
   PubMed Web of Science ®Google Scholar
• O’Neil, B. H., Allen, R., Spigel, D. R., Stinchcombe, T. E., Moore, D. T., Berlin, J. D., et al. (2007). High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 25:3644–3648.
   PubMed Web of Science ®Google Scholar
• O’Neil, B. H., Tepper, J. E. (2007). Current options for the management of rectal cancer. Curr Treat Options Oncol 8:331–338.
   PubMedGoogle Scholar
• Ocvirk, J., Brodowicz, T., Wrba, F., Ciuleanu, T. E., Kurteva, G., Beslija, S., et al. (2010). Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 16:3133–3143.
   PubMed Web of Science ®Google Scholar
• Okabe, M., Szakacs, G., Reimers, M. A., Suzuki, T., Hall, M. D., Abe, T., et al. (2008). Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 7:3081–3091.
   PubMed Web of Science ®Google Scholar
• Ouchi, K. F., Yanagisawa, M., Sekiguchi, F., Tanaka, Y. (2006). Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Cancer Chemother Pharmacol 57:693–702.
   PubMed Web of Science ®Google Scholar
• Pardi, D. S., Loftus, E. V., Jr., Kremers, W. K., Keach, J., Lindor, K. D. (2003). Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124:889–893.
   PubMed Web of Science ®Google Scholar
• Park, Y., Hunter, D. J., Spiegelman, D., Bergkvist, L., Berrino, F., van den Brandt, P. A., et al. (2005). Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. JAMA 294:2849–2857.
   PubMed Web of Science ®Google Scholar
• Pavillard, V., Agostini, C., Richard, S., Charasson, V., Montaudon, D., Robert, J. (2002). Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol 49:329–335.
   PubMed Web of Science ®Google Scholar
• Pedersen, T. R., Berg, K., Cook, T. J., Faergeman, O., Haghfelt, T., Kjekshus, J., et al. (1996). Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 156:2085–2092.
   PubMed Web of Science ®Google Scholar
• Peters, U., Sinha, R., Chatterjee, N., Subar, A. F., Ziegler, R. G., Kulldorff, M., et al. (2003). Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme. Lancet 361:1491–1495.
   PubMed Web of Science ®Google Scholar
• Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., et al. (2007). Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622–629.
   PubMed Web of Science ®Google Scholar
• Pinedo, H. M., Peters, G. F. (1988). Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653–1664.
   PubMed Web of Science ®Google Scholar
• Pitts, T. M., Morrow, M., Kaufman, S. A., Tentler, J. J., Eckhardt, S. G. (2009). Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol Cancer Ther 8:342–349.
   PubMed Web of Science ®Google Scholar
• Plasencia, C., Martinez-Balibrea, E., Martinez-Cardus, A., Quinn, D. I., Abad, A., Neamati, N. (2006). Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol 29:225–235.
   PubMed Web of Science ®Google Scholar
• Poincloux, L., Durando, X., Seitz, J. F., Thivat, E., Bardou, V. J., Giovannini, M. H., et al. (2009). Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer. Surg Oncol 18:357–365.
   PubMed Web of Science ®Google Scholar
• Poplin, E. A., Benedetti, J. K., Estes, N. C., Haller, D. G., Mayer, R. J., Goldberg, R. M., et al. (2005). Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 23:1819–1825.
   PubMed Web of Science ®Google Scholar
• Porschen, R., Arkenau, H. T., Kubicka, S., Greil, R., Seufferlein, T., Freier, W., et al. (2007). Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25:4217–4223.
   PubMed Web of Science ®Google Scholar
• Potocnik, U., Glavac, D., Dean, M. (2008). Common germline MDR1/ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability. Cancer Genet Cytogenet 183:28–34.
   PubMed Web of Science ®Google Scholar
• Poynter, J. N., Gruber, S. B., Higgins, P. D., Almog, R., Bonner, J. D., Rennert, H. S., et al. (2005). Statins and the risk of colorectal cancer. N Engl J Med 352:2184–2192.
   PubMed Web of Science ®Google Scholar
• Raftery, L., Goldberg, R. M. (2010). Optimal delivery of cytotoxic chemotherapy for colon cancer. Cancer J 16:214–219.
   PubMed Web of Science ®Google Scholar
• Reardon, J. T., Vaisman, A., Chaney, S. G., Sancar, A. (1999). Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 59:3968–3971.
   PubMed Web of Science ®Google Scholar
• Reid, M. E., Duffield-Lillico, A. J., Sunga, A., Fakih, M., Alberts, D. S., Marshall, J. R. (2006). Selenium supplementation and colorectal adenomas: an analysis of the nutritional prevention of cancer trial. Int J Cancer 118:1777–1781.
   PubMed Web of Science ®Google Scholar
• Reidy, D. L., Vakiani, E., Fakih, M. G., Saif, M. W., Hecht, J. R., Goodman-Davis, N., et al. (2010). Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol 28:4240–4246.
   PubMed Web of Science ®Google Scholar
• Rial, N. S., Meyskens, F. L., Gerner, E. W. (2009). Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention. Essays Biochem 46:111–124.
   PubMed Web of Science ®Google Scholar
• Robertson, J. D., Botwood, N. A., Rothenberg, M. L., Schmoll, H. J. (2009). Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. Clin Colorectal Cancer 8:59–60.
   PubMed Web of Science ®Google Scholar
• Rothenberg, M. L., Eckardt, J. R., Kuhn, J. G., Burris, H. A., 3rd, Nelson, J., Hilsenbeck, S. G., et al. (1996). Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128–1135.
   PubMed Web of Science ®Google Scholar
• Rothenberg, M. L., LaFleur, B., Levy, D. E., Washington, M. K., Morgan-Meadows, S. L., Ramanathan, R K., et al. (2005). Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 23:9265–9274.
   PubMed Web of Science ®Google Scholar
• Royal, R. E., Pingpank, J. F., Jr. (2008). Diagnosis and management of peritoneal carcinomatosis arising from adenocarcinoma of the colon and rectum. Semin Oncol 35:183–191.
   PubMed Web of Science ®Google Scholar
• Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., et al. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335:1001–1009.
   PubMed Web of Science ®Google Scholar
• Salonga, D., Danenberg, K. D., Johnson, M., Metzger, R., Groshen, S., Tsao-Wei, D. D., et al. (2000). Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322–1327.
   PubMed Web of Science ®Google Scholar
• Saltz, L. B., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., et al. (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019.
   PubMed Web of Science ®Google Scholar
• Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., et al. (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914.
   PubMed Web of Science ®Google Scholar
• Saltz, L. B., Niedzwiecki, D., Hollis, D., Goldberg, R. M., Hantel, A., Thomas, J. P., et al. (2007). Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 25:3456–3461.
   PubMed Web of Science ®Google Scholar
• Sanjoaquin, M. A., Allen, N., Couto, E., Roddam, A. W., Key, T. J. (2005). Folate intake and colorectal cancer risk: a meta-analytical approach. Int J Cancer 113:825–828.
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi, A., Martini, M., Molinari, F., Veronese, S., Nichelatti, M., Artale, S., et al. (2009). PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69:1851–1857.
   PubMed Web of Science ®Google Scholar
• Sauer, R, Becker, H, Hohenberger, W, Rodel, C, Wittekind, C, Fietkau, R, et al. (2004). Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740.
   PubMed Web of Science ®Google Scholar
• Saunders, M. P., Wilson, R., Peeters, M., Smith, R., Godwood, A., Oliver, S., et al. (2009). Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre phase I study. Cancer Chemother Pharmacol 64:665–672.
   PubMed Web of Science ®Google Scholar
• Schatzkin, A., Lanza, E., Corle, D., Lance, P., Iber, F., Caan, B., et al. (2000). Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 342:1149–1155.
   PubMed Web of Science ®Google Scholar
• Scheffer, G. L., Schroeijers, A. B., Izquierdo, M. A., Wiemer, E. A., Scheper, R. J. (2000). Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 12:550–556.
   PubMed Web of Science ®Google Scholar
• Schiffmann, S., Maier, T. J., Wobst, I., Janssen, A., Corban-Wilhelm, H., Angioni, C., et al. (2008). The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem Pharmacol 76:179–187.
   PubMed Web of Science ®Google Scholar
• Schmoll, H. J., Cartwright, T., Tabernero, J., Nowacki, M. P., Figer, A., Maroun, J., et al. (2007). Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 25:102–109.
   PubMed Web of Science ®Google Scholar
• Sengupta, S., Muir, J. G., Gibson, P. R. (2006). Does butyrate protect from colorectal cancer? J Gastroenterol Hepatol 21:209–218.
   PubMed Web of Science ®Google Scholar
• Shagisultanova, E. I., Piao, Z., Li, H. R., Malkhosyan, S. R. (2004). Topoisomerase II gene mutations in tumors and tumor cell lines with microsatellite instability. Cancer Lett 216:221–226.
   PubMed Web of Science ®Google Scholar
• Sharif, S., O’Connell, M. J., Yothers, G., Lopa, S., Wolmark, N. (2008). FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest 26:956–963.
   PubMed Web of Science ®Google Scholar
• Shaukat, A., Scouras, N., Schunemann, H. J. (2005). Role of supplemental calcium in the recurrence of colorectal adenomas: a metaanalysis of randomized controlled trials. Am J Gastroenterol 100:390–394.
   PubMed Web of Science ®Google Scholar
• Siddiqui, A. D., Piperdi, B. (2010). KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol 17:1168–1176.
   PubMed Web of Science ®Google Scholar
• Sigmond, J., Comijn, E. M., Kamphuis, J. A., Peters, G. J. (2004). Combinations of 5-fluorouracil with UCN-01 or staurosporine. Nucleosides Nucleotides Nucleic Acids 23:1503–1506.
   PubMed Web of Science ®Google Scholar
• Singer, C. F., Hudelist, G., Lamm, W., Mueller, R., Czerwenka, K., Kubista, E. (2004). Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors. Endocr Relat Cancer 11:861–869.
   PubMed Web of Science ®Google Scholar
• Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., et al. (2008). EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311–2319.
   PubMed Web of Science ®Google Scholar
• Souglakos, J., Androulakis, N., Syrigos, K., Polyzos, A., Ziras, N., Athanasiadis, A., et al. (2006). FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94:798–805.
   PubMed Web of Science ®Google Scholar
• Spigel, D. R., Greco, F. A., Waterhouse, D., Shipley, D., Lane, C. M., Vazquez, E. R., et al. (2010). Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer. Clin Adv Hematol Oncol 8:480–485.
   PubMedGoogle Scholar
• Sturmer, T., Glynn, R. J., Lee, I. M., Manson, J. E., Buring, J. E., Hennekens, C. H. (1998). Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians’ Health Study. Ann Intern Med 128:713–720.
   PubMed Web of Science ®Google Scholar
• Sun, Y., Sun, J., Shi, S., Jing, Y., Yin, S., Chen, Y., et al. (2009). Synthesis, transport and pharmacokinetics of 5′-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine. Mol Pharm 6:315–325.
   PubMed Web of Science ®Google Scholar
• Taylor, P. R., Greenwald, P. (2005). Nutritional interventions in cancer prevention. J Clin Oncol 23:333–345.
   PubMed Web of Science ®Google Scholar
• Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., Willingham, M. C. (1987). Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84:7735–7738.
   PubMed Web of Science ®Google Scholar
• Thompson, P. A., Wertheim, B. C., Zell, J. A., Chen, W. P., McLaren, C. E., LaFleur, B. J., et al. (2010). Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. Gastroenterology 139:797–805.
   PubMed Web of Science ®Google Scholar
• Tournigand, C., Andre, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., et al. (2004). FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237.
   PubMed Web of Science ®Google Scholar
• Townsley, C. A., Major, P., Siu, L. L., Dancey, J., Chen, E., Pond, G. R., et al. (2006). Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 94:1136–1143.
   PubMed Web of Science ®Google Scholar
• Tung, B. Y., Emond, M. J., Haggitt, R. C., Bronner, M. P., Kimmey, M. B., Kowdley, K. V., et al. (2001). Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 134:89–95.
   PubMed Web of Science ®Google Scholar
• Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., 3rd, Carrato, A., et al. (2005). Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696–2704.
   PubMed Web of Science ®Google Scholar
• Tyagi, P. (2005). Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. Clin Colorectal Cancer 5:24–26.
   PubMedGoogle Scholar
• Tytherleigh, M. G., Warren, B. F., Mortensen, N. J. (2008). Management of early rectal cancer. Br J Surg 95:409–423.
   PubMed Web of Science ®Google Scholar
• Van Cutsem, E., Dicato, M., Haustermans, K., Arber, N., Bosset, J. F., Cunningham, D., et al. (2008). The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Ann Oncol 19: vi1–8.
   Web of Science ®Google Scholar
• Van Cutsem, E., Kohne, C. H., Hitre, E., Zaluski, J., Chang Chien, C. R., Makhson, A., et al. (2009a). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417.
   PubMed Web of Science ®Google Scholar
• Van Cutsem, E., Labianca, R., Bodoky, G., Barone, C., Aranda, E., Nordlinger, B., et al. (2009b). Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27:3117–3125.
   PubMed Web of Science ®Google Scholar
• Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., et al. (2007). Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol, 25, 1658–64.
   PubMed Web of Science ®Google Scholar
• Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., et al. (2001). Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097–4106.
   PubMed Web of Science ®Google Scholar
• Veronese, M. L., Sun, W., Giantonio, B., Berlin, J., Shults, J., Davis, L., et al. (2005). A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. Br J Cancer 92:1846–1849.
   PubMed Web of Science ®Google Scholar
• Vincenzi, B., Santini, D., Rabitti, C., Coppola, R., Beomonte Zobel, B., Trodella, L., et al. (2006). Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer 94:792–797.
   PubMed Web of Science ®Google Scholar
• Wactawski-Wende, J., Kotchen, J. M., Anderson, G. L., Assaf, A. R., Brunner, R. L., O’Sullivan, M. J., et al. (2006). Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 354:684–696.
   PubMed Web of Science ®Google Scholar
• Wang, W., McLeod, H. L., Cassidy, J., Collie-Duguid, E. S. (2007). Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks. Cancer Chemother Pharmacol 59:839–845.
   PubMed Web of Science ®Google Scholar
• Webley, S. D., Welsh, S. J., Jackman, A. L., Aherne, G. W. (2001). The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition. Br J Cancer 85:446–452.
   PubMed Web of Science ®Google Scholar
• West, N. P., Hohenberger, W., Weber, K., Perrakis, A., Finan, P. J., Quirke, P. (2010). Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol 28:272–278.
   PubMed Web of Science ®Google Scholar
• Wolmark, N., Rockette, H., Mamounas, E., Jones, J., Wieand, S., Wickerham, D. L., et al. (1999). Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17:3553–3559.
   PubMed Web of Science ®Google Scholar
• Wolmark, N., Wieand, S., Kuebler, J., Colangelo, L., O’Connell, M. J., Yothers, G. (2008). A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07. J Clin Oncol 26:1008S.
   PubMedGoogle Scholar
• Wood, J. M., Bold, G., Buchdunger, E., Cozens, R., Ferrari, S., Frei, J., et al. (2000). PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178–2189.
   PubMed Web of Science ®Google Scholar
• Xu, Y., Fang, F., Ludewig, G., Jones, G., Jones, D. (2004). A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23:419–429.
   PubMed Web of Science ®Google Scholar
• Yan, T. D., Black, D., Savady, R., Sugarbaker, P. H. (2006). Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 24:4011–4019.
   PubMed Web of Science ®Google Scholar
• Ychou, M., Raoul, J. L., Douillard, J. Y., Gourgou-Bourgade, S., Bugat, R., Mineur, L., et al. (2009). A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 20:674–680.
   PubMed Web of Science ®Google Scholar
• Yonezawa, A., Masuda, S., Yokoo, S., Katsura, T., Inui, K. (2006). Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 319:879–886.
   PubMed Web of Science ®Google Scholar